Nakajima, Takako Eguchi http://orcid.org/0000-0002-4589-2335
Yamaguchi, Kensei
Boku, Narikazu
Hyodo, Ichinosuke
Mizusawa, Junki
Hara, Hiroki
Nishina, Tomohiro
Sakamoto, Takeshi
Shitara, Kohei
Shinozaki, Katsunori
Katayama, Hiroshi
Nakamura, Shinichiro
Muro, Kei
Terashima, Masanori
Funding for this research was provided by:
The National Cancer Research and Development Fund (26-A-4, 29-A-3)
The Ministry of Health, Labour and Welfare of Japan (Grant-in-Aid for Clinical Cancer Research (H26-144))
Japan Agency for Medical Research and Development (JP16ck0106139, JP18ck0106351)
Article History
Received: 2 November 2019
Accepted: 21 January 2020
First Online: 8 February 2020
Compliance with ethical standards
:
: Dr. Nakajima reports grants from AMED, during the conduct of the study; grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Merck Serono Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Sanofi K.K., grants from Daiichi Sankyo Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Nippon Kayaku Co., Ltd., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants from Astellas Pharma Inc., grants and personal fees from Sumitomo Dainippon Pharma Co., Ltd., grants from Eisai Co., grants and personal fees from MSD K.K., grants from Solasia Pharma K.K., grants from AstraZeneca K.K., personal fees from Sawai Pharmaceutical Co., personal fees from Bayer Yakuhin, Ltd., personal fees from Bristol-Myers Squibb, personal fees from Mochida Pharmaceutical Co., Ltd., personal fees from Kyowa Kirin Co., Ltd., personal fees from Maruho Co., Ltd., personal fees from Teijin Pharma Limited, and grants from AMED unrelated to the present study. Dr. Yamaguchi reports grants from AMED, during the conduct of the study; grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Merck Serono Co., Ltd., personal fees from Takeda Pharmaceutical Co., Ltd., grants and personal fees from Daiichi Sankyo Co., Ltd., grants and personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Elli Lilly Japan K.K., personal fees from Bristol-Myers Squibb, grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Boehringer Ingelheim, grants from Gilead Sciences, Inc., grants from MSD K.K., and grants from Yakult Honsha Co. unrelated to the present study. Dr. Boku reports grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., and personal fees from Eli-Lilly Japan K.K. unrelated to the present study. Dr. Hyodo reports grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Daiichi Sankyo Co., Ltd., and grants and personal fees from Ono Pharmaceutical Co., Ltd., unrelated to the present study. Dr. Mizusawa reports grants from Ministry of Health, Labour and Welfare, Japan, grants from AMED, during the conduct of the study; personal fees from Chugai Pharmaceutical Co., Ltd., unrelated to the present study. Dr. Hara reports grants from AMED, during the conduct of the study; grants from Astra Zeneca K.K., grants and personal fees from Daiichi Sankyo Co., Ltd., grants from Sumitomo Dainippon Pharma Co., Ltd., personal fees from Eli Lilly Japan K.K., grants from Merck Serono Co., Ltd., grants and personal fees from MSD K.K., grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants from Eisai Co., grants from LSK BioPharma, grants from Incyte, grants from Pfizer Inc., grants from Boehringer Ingelheim, grants from BeiGene, grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from Bristol-Myers Squibb, personal fees from Yakult Honsha Co., personal fees from Sanofi K.K., and personal fees from Takeda Pharmaceutical Co., Ltd., unrelated to the present study. Dr. Nishina reports grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants from Daiichi Sankyo Co., Ltd., grants from MSD K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Eli Lilly Japan K.K., and grants from Sumitomo Dainippon Pharma Co., Ltd., unrelated to the present study. Dr. Sakamoto has nothing to disclose. Dr. Shitara reports grants and personal fees from Astellas Pharma Inc., grants and personal fees from Eli Lilly Japan K.K., personal fees from Bristol-Myers Squibb, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Pfizer Inc., grants and personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Novartis, personal fees from AbbVie, personal fees from Yakult Honsha, grants from Sumitomo Dainippon Pharma Co., Ltd., grants from Daiichi Sankyo Co., Ltd., grants from Taiho Pharmaceutical Co., Ltd., grants from Chugai Pharmaceutical Co., Ltd., grants and personal fees from MSD K.K., and grants from Medi-Science, Inc. unrelated to the present work. Dr. Shinozaki reports personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Mochida Pharmaceutical Co., Ltd., personal fees from Merck Serono Co., Ltd., personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Yakult Honsha Co., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Eisai Co., personal fees from Shionogi & Co., personal fees from Eli Lilly Japan K.K., personal fees from Sanofi K.K., personal fees from Daiichi Sankyo Co., Ltd., personal fees from Bayer Yakuhin, Ltd., and personal fees from Pfizer Inc. unrelated to the present study. Dr. Katayama reports grants and nonfinancial support from the Ministry of Health, Labour and Welfare, Japan, grants and nonfinancial support from AMED, during the conduct of the study, and personal fees from Johnson & Johnson K.K. unrelated to the present study. Dr. Nakamura has nothing to disclose. Dr. Muro reports grants from Gilead Sciences, Inc., grants from Daiichi Sankyo Co., Ltd., grants from Shionogi & Co., grants from MSD K.K., grants from Sanofi K.K., grants from Kyowa Kirin Co., Ltd., grants from Merck Serono Co., Ltd., grants from Pfizer Inc., personal fees from Eli Lilly Japan K.K., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Sanofi K.K., personal fees from Bayer Yakuhin, Ltd., and personal fees from Bristol-Myers Squibb unrelated to the present study. Dr. Terashima reports personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Bristol-Myers Squibb, personal fees from Yakult Honsha, personal fees from Takeda Pharmaceutical Co., Ltd., personal fees from Eli Lilly Japan K.K., personal fees from Pfizer Inc., and personal fees from Daiichi Sankyo Co., Ltd., unrelated to the present study.
: The review committees of the JCOG and WJOG and the institutional review boards of all participating institutions approved the study protocol, which was conducted according to the Declaration of Helsinki and Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects.
: Informed consent to be included in the study was obtained from all patients.
Free to read: This content has been made available to all.